Thierry Dervieux

Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study

J. Kremer, D. Furst, T. Dervieux, 2005, Annals of the rheumatic diseases.

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

J. Kremer, T. Dervieux, N. Greenstein, 2006, Arthritis and rheumatism.

Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.

J. Kremer, D. Furst, T. Dervieux, 2004, Pharmacogenetics.

Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.

J. Kremer, M. Weisman, D. Furst, 2006, Arthritis and rheumatism.

HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis.

J. Marcelletti, T. Dervieux, Katie Smith, 2003, Clinical chemistry.

Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.

Rong W. Zablocki, J. Kremer, T. Dervieux, 2010, Rheumatology.

Gene–gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis

J. Kremer, N. Penrod, H. Guchelaar, 2009, Pharmacogenetics and genomics.